Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0374 • ACR Convergence 2023
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Bashayer Alnuaimi¹, Michelle Batthish², Roberta A Berard³, Gilles Boire⁴, Sarah Campillo¹, Amieleena Chhabra⁵, Julie Couture⁶, Paul Dancey⁷, Brian Feldman⁸, Tommy Gerschman⁹, Julie Herrington¹⁰, Kristin Houghton¹¹, Adam Huber¹², Claire LeBlanc¹, Lillian Lim¹³, Jean-Philippe Proulx-Gauthier⁶, Heinrike Schmeling¹⁴, Rosie Scuccimarri¹, Lori Tucker¹⁵, Jaime Guzman¹⁵, Gaëlle Chédeville¹ and For The CAPRI Registry Investigators¹⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada, ³Children's Hospital - London Health Sciences Centre, London, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵British Columbia Hospital, Vancouver, BC, Canada, ⁶CHU de Quebec- Universite Laval, Quebec City, QC, Canada, ⁷Memorial University of Newfoundland, St. John's, NL, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹British Columbia Children's Hospital, Burnaby, BC, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹British Columbia University, Vancouver, BC, Canada, ¹²IWK Health Centre, Halifax, NS, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁶CAPRI, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
Abstract Number: 0450 • ACR Convergence 2023
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Martinus Van de Laar¹, Martijn Oude Voshaar¹, Peter ten Klooster¹, Danyta Tedjo² and celine van de laar³, ¹University of Twente, Hengelo (OV), Netherlands, ²TiH @ University of Twente, Hengelo (OV), Netherlands, ³Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
Abstract Number: 0840 • ACR Convergence 2023
Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study
Xiaofeng Zeng¹, chanyuan wu², Jiankang Hu³, SHENGYUN LIU⁴, Zhenyu Jiang⁵, Jingyang Li⁶, Xiaoxia Wang⁷, Ju Liu⁸, Chaofan Yuan⁹, Guang Yang¹⁰ and Chris Liang¹⁰, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Pingxiang People’s Hospital, PingXiang, China, ⁴The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, China, ⁵The First Hospital of Jilin University, Changchun, China, ⁶Zhuzhou Central Hospital, Zhuzhou, China, ⁷Second Hospital of Shanxi Medical University, Taiyuan, China, ⁸Jiujiang No. 1 People’s Hospital, JiuJiang, China, ⁹Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing, China, ¹⁰Hangzhou Highlightll Pharmaceutical Co., Ltd, HangZhou, China
Background/Purpose: None of the currently approved treatments for rheumatoid arthritis (RA) can achieve ACR50 in >50% of the patients, and 5 – 20% of the…
Abstract Number: 1326 • ACR Convergence 2023
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Koji Kato², Boulos Haraoui³, Maureen Rischmueller⁴, Yanxi Liu², Nasser Khan⁵, Heidi Camp² and Ricardo Xavier⁶, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²AbbVie, Inc., North Chicago, IL, ³Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁵Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: To evaluate the long-term safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, through week 204 in patients with RA from the long-term…
Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Benjamin de Valence de Minardiere¹, Marion Delaune², Yann Nguyen³, Vincent Jachiet⁴, Mael Heiblig⁵, Alexis Jean⁶, Pierrick Henneton⁷, stanislas Riescher-tuczkiewicz⁸, Philippe Guilpain⁷, Hervé Lobbes⁹, Guillaume Le Guenno¹⁰, Nicolas Schleinitz¹¹, Valentin Lacombe¹², Vincent Langlois¹³, Roderau Outh¹⁴, Julien Vinit¹⁵, Jean-Philippe Martellosio¹⁶, Paul Decker¹⁷, Alexandre Vlakos¹⁸, Thomas Moulinet¹⁹, Yannick Dieudonne²⁰, Adrien Bigot²¹, Louis Terriou²², Bertrand De Maleprade²³, Guillaume Denis²⁴, Jonathan Broner²⁵, Marie Kostine²⁶, Sébastien Humbert²⁷, Benjamin Terrier²⁸, Sophie Georgin-Lavialle²⁹, Olivier Fain³⁰, Arsène Mekinian¹, Marjolaine MORGAND¹, Thibault Comont² and Jerome Hadjadj¹, ¹Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ²Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ⁴Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France, ⁵Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France, ⁶Internal Medicine Department, Bordeaux University, Faculty of Medicine, Bordeaux University Hospital, Bordeaux, France, ⁷CHU Montpellier, Montpellier, France, ⁸CHU de Nantes, Nantes, France, ⁹CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁰Internal Medicine Department, Clermont-Ferrand University, Faculty of Medicine, Estaing University Hospital, Clermont-Ferrand, France, ¹¹Aix Marseille university, AP-HM, Marseille, France, ¹²Internal Medicine Department, Anger Hospital, Clermont-Ferrand, France, ¹³Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France, ¹⁴Internal Medicine Department, Perpignan Hospital Center, Perpignan, France, ¹⁵Service de Médecine Interne, CH William Morey, Chalon sur Saône, France., Chalon sur Saône, France, ¹⁶Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ¹⁷Nancy hospital, France, Nancy, France, ¹⁸Vesoul Hospital, Vesoul, France, ¹⁹Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ²⁰Department of Clinical Immunology and Internal Medicine, National Reference Centre for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, ²¹Internal Medicine Department, Tours University, Faculty of Medicine, Tours University Hospital, Tours, France, ²²Service de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France, ²³Rouen hospital, France, Rouen, France, ²⁴Service d'hématologie, CH de Rochefort, Rochefort, France, ²⁵CHU de Nimes, Nimes, France, ²⁶Bordeaux University Hospital, Bordeaux, France, ²⁷Besançon University Hospital, Besançon, France, ²⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²⁹AP-HP, Tenon hospital, Paris, France, ³⁰Hopital SAINT ANTOINE APHP, Paris, France
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…
Abstract Number: 2160 • ACR Convergence 2023
Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes
Paula David¹, Andrea Di Matteo¹, Or Hen¹, Shouvik Dass², Helena Marzo-Ortega³, Paul Emery⁴, Benazir Saleem² and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported on difficult to treat Rheumatoid Arthritis (RA) in nearly 1600 patients treated with biologic (b) or target synthetic (ts) DMARDs including…
Abstract Number: 2453 • ACR Convergence 2023
Development of a Hydroxychloroquine Retinopathy Prediction Score
April Jorge¹, Ronald Melles², Baijun Zhou¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Kaiser Permanente Northern California, Redwood City, CA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important medication for SLE and other rheumatic diseases, but its major adverse event is HCQ retinopathy. Weight-based HCQ dose is…
Abstract Number: 0375 • ACR Convergence 2023
Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands
Lea Höfel, Bruno Eppler, Johannes-Peter Haas and Boris Hugle, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA), and intolerance to the drug frequently leads to discontinuation…
Abstract Number: 0451 • ACR Convergence 2023
Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Maya Buch¹, Jose A Gomez-Puerta², Gerd Burmester³, Bernard G. Combe⁴, Vijay Rajendran⁵, Pieter-Jan Stiers⁶, Paul Van Hoek⁷, Katrien Van Beneden⁷, Jacques-Eric Gottenberg⁸, Yoshiya Tanaka⁹, Daniel Aletaha¹⁰, René Westhovens¹¹ and Roberto F. Caporali¹², ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Department of Rheumatology, Montpellier University, Montpellier, France, ⁵Clinical Research, Galapagos NV, Mechelen, Belgium, ⁶Biostatistics, Galapagos NV, Mechelen, Belgium, ⁷Medical Safety, Galapagos NV, Mechelen, Belgium, ⁸Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁹University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ¹¹Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor for the treatment of moderate to severe active RA. A previous pooled analysis reported…
Abstract Number: 0983 • ACR Convergence 2023
Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study
I-Feng Lin¹, Hsin-Hua Chen², Theodore Tsai³ and Nicole Huang⁴, ¹National Yang Ming Chiao Tung University, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Takeda Vaccines, Cambridge, MA, ⁴Master of Public Health Program, National Yang Ming Chiao Tung University, Taipei, Taiwan
Background/Purpose: Dengue is the leading vectorborne disease globally with half of the global population at risk, including Puerto Rico in the United States. Previously, we…
Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
YOSHIHIKO HOSHIDA¹, Atsuko Tsujii², SHIRO OHSHIMA³, YUKIHIKO SAEKI³, MASATO YAGITA⁴, TOMOYA MIYAMURA⁵, Masao Katayama⁶, TOMONORI KAWASAKI⁷, YASUSHI HIRAMATSU⁸, Hisaji Oshima⁹, TOSHIHIKO MURAYAMA¹⁰, SHINJI HIGA¹¹, KAZUYA KURAOKA¹², FUMINORI HIRANO¹³, KENJI ICHIKAWA¹⁴, MITSUTOSHI KUROSAWA¹⁵, HIROAKI SUZUKI¹⁵, NORIYUKI CHIBA¹⁶, TAKAO SUGIYAMA¹⁷, YUKO MINAMI¹⁸, HITOSHI NIINO¹⁹, ATSUSHI IHATA²⁰, IKUO SAITO²¹, AKIKO MITSUO²², TOSHITAKA MAEJIMA²³, ATSUHIRO KAWASHIMA²⁴, HIROSHI TSUTANI²⁵, KOICHIRO TAKAHI²⁶, TAKAHIKO KASAI²⁷, YOKO SHINNO²⁸, YOSHIRO TACHIYAMA²⁹, NORIHIRO TERAMOTO³⁰, KENICHI TAGUCHI³¹, SHINJI NAITO³², SHIGERU YOSHIZAWA³³, MASAHIRO ITO³⁴, YASUO SUENAGA³⁵, Shunsuke Mori³⁶, SHOICHI NAGAKURA³⁷, NORIE YOSHIKAWA³⁸, MITSUHARU NOMOTO³⁹, ATSUHISA UEDA⁴⁰, SHOUHEI NAGAOKA⁴¹, YUKIO TSUURA⁴², KEIGO SETOGUCHI⁴³, SHOJI SUGII⁴⁴, Asami Abe⁴⁵, TOSHIAKI SUGAYA⁴⁶, HIROYUKI SUGAHARA⁴⁷, MASAHIRO KOSETO⁴⁸, YASUO KUNUGIZA², NORISHIGE IIZUKA³, RYOSUKE YOSHIHARA⁴, HIROKI YABE⁵, TOMOAKI FUJISAKI⁶, EIICHI MORII⁷, MORISHIGE TAKESHITA⁸, MASAKAZU SATO⁹, KAZUYOSHI SAITO¹⁰, Kiyoshi Matsui¹¹, YASUHIKO TOMITA¹², HIROSHI FURUKAWA¹³ and Shigeto Tohma¹⁴, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ²Osaka Minami Medical Center, Kawachinagano City, Japan, ³National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ⁴Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁵NHO Kyushu Medical Center, Fukuoka, Japan, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁷NHO Nagoya Medical Center, Nagoya, Japan, ⁸Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹National Tokyo Medical Center, Tokyo, Japan, ¹⁰NHO Kumamoto Medical Center, Kumamoto, Japan, ¹¹Daini Osaka Police Hospital, Osaka, Japan, ¹²NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, ¹³NHO Asahikawa Medical Center, Asahikawa, Japan, ¹⁴Nissei hospital, Sapporo, Japan, ¹⁵NHO Hokkaido Cancer Center, Sapporo, Japan, ¹⁶NHO Morioka Medical Center, Morioka, Japan, ¹⁷NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹⁸NHO Ibarakihigashi Hospital, Ibaraki, Japan, ¹⁹NHO Yokohama Medical Center, Yokohama, Japan, ²⁰National Hospital Organization Yokohama Medical Center, Yokohama, Japan, ²¹NHO Sagamihara Hospital, Sagamihara, Japan, ²²NHO Disaster Medical Center, Tachikawa, Japan, ²³NHO Shinshu Ueda Medical Center, Ueda, Japan, ²⁴NHO Kanazawa Medical Center, Kanazawa, Japan, ²⁵NHO Awara Hospital, Awara, Japan, ²⁶NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ²⁷Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, ²⁸NHO Okayama Medical Center, Okayama, Japan, ²⁹NHO Hiroshima Nishi Medical Center, Otake, Japan, ³⁰NHO Shikoku Cancer Center, Matsuyama, Japan, ³¹NHO Kyushu Cancer Center, Fukuoka, Japan, ³²NHO Ureshino Medical Center, Ureshino, Japan, ³³NHO Fukuoka Hospital, Fukuoka, Japan, ³⁴NHO Nagasaki Medical Center, Omura, Japan, ³⁵NHO Beppu Medical Center, Beppu, Japan, ³⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ³⁷NHO Kumamoto Minami Hospital, Uki, Japan, ³⁸NHO Miyakonojo Medical Center, Miyakonojo, Japan, ³⁹NHO Kagoshima Medical Center, Kagoshima, Japan, ⁴⁰Yokohama City University Medical Center, Yokohama, Japan, ⁴¹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴²Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, ⁴³Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ⁴⁴Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ⁴⁵Niigata Rheumatic Center, Shibata, Japan, ⁴⁶Fuchu Hospital, Izumi, Japan, ⁴⁷Sumitomo Hospital, Osaka, Japan, ⁴⁸Nippon Life Hospital, Osaka, Japan, ⁴⁹JCHO Hoshigaoka Medical Center, Hirakata, Japan, ⁵⁰Kishiwada City Hospital, Kishiwada, Japan, ⁵¹Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ⁵²Ako Central Hospital, Ako, Japan, ⁵³Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁵⁴Osaka University, Suita, Japan, ⁵⁵Fukuoka University, Fukuoka, Japan, ⁵⁶Kurashiki University of Science and the Arts, Kurashiki, Japan, ⁵⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵⁸Hyogo Medical University, Nishinomiya, Japan, ⁵⁹International University of Health and Welfare, Otawara City, Japan, ⁶⁰NHO Tokyo National Hospital, Kiyose, Japan, ⁶¹NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
Abstract Number: 1675 • ACR Convergence 2023
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei², Chi-Fang Wu², Hui Zhao², Suja Rajan³, Heather Lin² and Sharon Giordano², ¹MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX
Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
Abstract Number: 2162 • ACR Convergence 2023
Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure
René Westhovens¹, Rieke Alten², Lorenzo Dagna³, Arthur Kavanaugh⁴, Kevin Withrop⁵, Jane Barry⁶, Robin Besuyen⁷, Claudio Corallo⁸, Dick de Vries⁹, Nicolas Martin¹⁰, Chris Watson⁶, Mark C. Genovese¹¹, Alberto Spindler¹², Mykola Stanislavchuk¹³, Maria Greenwald¹⁴ and Paul Emery¹⁵, ¹Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ³Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁴Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁵Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁶Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁷Clinical Development, Galapagos BV, Leiden, Netherlands, ⁸Medical Affairs, Galapagos Biopharma Italy S.R.L., Milan, Italy, ⁹Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹⁰Biostatistics, Galapagos NV, Mechelen, Belgium, ¹¹Clinical Development, Gilead Sciences Inc., Foster City, CA, ¹²Rheumatology Section, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina, ¹³Rheumatology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine, ¹⁴Rheumatology, Desert Medical Advances, Palm Desert, CA, ¹⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: DARWIN 3 (NCT02065700) is a long-term extension (LTE) study assessing the safety and efficacy of filgotinib (FIL) in patients with rheumatoid arthritis (RA) and…
Abstract Number: 2512 • ACR Convergence 2023
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Jacques-Eric Gottenberg¹, Nathanaël Sedmak², Pierre Tran Ba Loc², Thibaut Fabacher², Thibaut Bahougne², Cécile Arnold², Guillaume Desjeux³, Hervé Servy⁴, Nicolas Meyer², Erik Sauleau², Raphaele Seror⁵ and Eden Sebbag⁶, ¹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³e-Health Services Sanoia, Gemenos, France, ⁴e-Health Services Sanoia, La Ciotat, France, ⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁶Université de Strasbourg, Strasbourg, France
Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].